Skip to main content

Dossiers. Agency questions. Inspections. Seal Submissions. Your dossier, drawn from the record.

In Seal Submissions, Neil drafts dossier sections and agency answers from the published record, each line linked to its source, for a person to sign.

Section 3.2.P.5.1, Specification(s), of the Module 3 Blubber Biologics drafts for Rookery Bio, for mAb-24 drug product, 10R vial, at 09:40 on Monday 7 December. Neil drafted it at 09:12 from SPEC-DP-24 v3: 19 tests, each with its acceptance criterion and its method at the version in force, every line a link to its entity. One gap: charge variants, where the specification gives 55.0 to 75.0% and does not say of which peak, while QCM-025 v3 reports the main peak. The section is for H. Tanaka, the QC manager who owns it, to settle and approve.
Submissions › Rookery Bio › 3.2.P.5.1
1 gap
mAb-24 drug product, 10R vialMon 7 Dec, 09:40

3.2.P.5.1 Specification(s)

  1. ClarityClear to slightly opalescentQCM-002 v3
  2. ColourColourless to slightly yellowQCM-003 v3
  3. Visible particlesPractically free of particlesQCM-005 v4
  4. pH5.7 to 6.3QCM-007 v2
  5. Osmolality270 to 330 mOsm/kgQCM-008 v2
  6. Extractable volumeAt least the labelled volumeQCM-011 v2
  7. IdentityMatches the reference standardQCM-018 v3
  8. Assay95.0 to 105.0%QCM-014 v5
  9. Monomer, SE-HPLCAt least 95.0%QCM-021 v6
  10. CE-SDS, reducedAt least 95.0%QCM-023 v4
  11. CE-SDS, non-reducedAt least 92.0%QCM-023 v4
  12. Charge variants55.0 to 75.0%QCM-025 v3
  13. Potency, cell-based80 to 125%QCM-041 v5
  14. Binding, ELISA70 to 130%QCM-038 v4
  15. Polysorbate 800.15 to 0.25 mg/mLQCM-027 v2
  16. Subvisible particlesAt most 6,000 and 600 a vialQCM-012 v3
  17. Closure integrityNo leak in the sampleQCM-016 v2
  18. EndotoxinAt most 0.5 EU/mLQCM-031 v4
  19. SterilityNo growthQCM-033 v5

Neil's draft

For H. Tanaka

Charge variants

SPEC-⁠DP-⁠24 v3 gives 55.0 to 75.0% and does not say of which peak. QCM-⁠025 v3 reports the main peak; lot 26-⁠0917 read 64.1% main peak.

Approve the section
Drafted by Neil from SPEC-⁠DP-⁠24 v3: each test and its criterion, as the specification gives themEach of the 18 methods at its version in force. Every line opens its entityThe one line Neil could not tie to a source, left for its owner, not filled inH. Tanaka, who owns the section, settles the gap and approves itEvery line linked to its sourceNeil drafts, a person approvesSPEC-⁠DP-⁠24 v3, published, with its 19 tests and their criteriaEach method's version in force on Mon 7 Dec, from QCM-⁠002 v3 to QCM-⁠041 v5Found as Neil read each criterion against what its method reports

Every line, back to its source.

Today a section is pasted together from copies on a shared drive, and nobody can say which version a number came from.

Compared onTodaySeal Submissions
A dossier sectionPasted into Word from copies on a shared driveDrafted by Neil from the published entities
A number in itChecked by hand against a PDFLinked to its entity and version
Who says it is rightWhoever saw the last copyIts owner, who signs it
The agency's questionChased round QC and QAAnswered from the record, each statement linked
The inspectionA war room and a binder of copiesA read-only room in the record itself

The agency asks. The record answers.

Neil drafts the answer from the entities it rests on, each statement linked at its version, and a person approves it before it is sent.

Question 3 of the agency's information request for mAb-24, passed on by Rookery Bio on Monday 30 November and due Monday 7 December: Explain how inhibition of the endotoxin test by the drug product is detected, and how it was resolved. Neil's draft answer, at 14:05: Every run of QCM-031 v4 is spiked, and a run whose spike recovery falls outside 50 to 200% reports no result. On lot 26-0917, run R-1005-02 recovered 31%. H. Tanaka, the QC manager, approved its assessment on Tue 10 Nov: the product inhibited the test. The retest, R-1005-03 on Fri 13 Nov, was diluted further within the method's maximum valid dilution and read 0.12 EU/mL, against at most 0.5 EU/mL. Its five sources, each at the version Neil read: QCM-031, v4, in force since 14 Jul; R-1005-02, Reader PL-03, Mon 9 Nov; Invalid run assessment, H. Tanaka, Tue 10 Nov; R-1005-03, Retest, Fri 13 Nov; SPEC-DP-24, v3. The answer is for E. Marchetti, the QP, to approve and share with Rookery Bio, which sends it to the agency.
Submissions › Rookery Bio › Question 3
Draft
Information request, via Rookery BioMon 30 Nov, 14:20

Question 3

Explain how inhibition of the endotoxin test by the drug product is detected, and how it was resolved.

Drafted by Neil, 14:05

Every run of QCM-⁠031 v4 is spiked, and a run whose spike recovery falls outside 50 to 200% reports no result.source 1

On lot 26-⁠0917, run R-⁠1005-⁠02 recovered 31%. H. Tanaka, the QC manager, approved its assessment on Tue 10 Nov: the product inhibited the test.source 2source 3

The retest, R-⁠1005-⁠03 on Fri 13 Nov, was diluted further within the method's maximum valid dilution and read 0.12 EU/mL, against at most 0.5 EU/mL.source 4source 1source 5

Sources

Due Mon 7 Dec
For E. MarchettiApprove the answer
Question 3 of the agency's request, passed on by Rookery Bio on Mon 30 NovNeil's draft at 14:05, from the entities the answer rests onEach source opens at the version Neil read, for E. Marchetti to checkE. Marchetti approves it and shares it with Rookery Bio, which sends it to the agencyEvery statement linked to its sourceSent by Rookery Bio, through its own gatewayThe endotoxin method: every run spiked, and a recovery outside 50 to 200% reports no resultLot 26-⁠0917's run on reader PL-⁠03: spike recovery 31%, no resultApproved by H. Tanaka, the QC manager: the product inhibited the testThe retest, at a further dilution: 0.12 EU/mLThe specification: endotoxin at most 0.5 EU/mL

The inspector reads the record itself.

A read-only room scoped to what the inspection covers, keeping every request made in it and what was shown for each.

The inspector's room for the inspection of Line 2, from Tue 22 Sep, at 10:30 on its second day, Wednesday 25 November. It is read-only. The day's requests: 10, at 09:04, Line 2's deviations since Tue 22 Sep, shown at 09:15; 11, at 09:12, Training on SOP-FIL-007 v13, for Line 2's operators, shown at 09:26; 12, at 09:20, Media fill MF-26-02 and the interventions it covers, shown at 09:31; 13, at 09:33, The settle, contact and glove plates of lot 26-0917's fill, shown at 09:40; 14, at 09:41, How was lot 26-0917 released after an intervention its record did not show?, shown at 09:58; 15, at 10:24, CAPA-019 and the feed track it replaced, open. Request 14 is open beside them, with what S. Amato showed for it at 09:58: Lot 26-0917, Certified and released by E. Marchetti, QP; Results, 19 of 19 in, sterility among them; DEV-041, Closed by S. Amato after the sterility result; INT-07, The jam cleared as a qualified intervention; 61 open vials rejected; EM plates, Settle, contact and glove plates of the fill in limits; Bulk hold, 29 h 40 min accepted by QA, 0 CFU in 100 mL; Earlier lots, Four jams assessed: no product impact; SOP-FIL-007 v13, A cleared jam is now recorded before the restart. The inspector can make a new request, and can change nothing.
Submissions › Inspection › Request 14
Read-only
Day 2, Wed 25 Nov10:30

Line 2, from Tue 22 Sep

  1. 10Line 2's deviations since Tue 22 SepShown 09:15
  2. 11Training on SOP-⁠FIL-⁠007 v13, for Line 2's operatorsShown 09:26
  3. 12Media fill MF-⁠26-⁠02 and the interventions it coversShown 09:31
  4. 13The settle, contact and glove plates of lot 26-⁠0917's fillShown 09:40
  5. 14How was lot 26-⁠0917 released after an intervention its record did not show?Shown 09:58
  6. 15CAPA-⁠019 and the feed track it replacedOpen
New request

Request 14

Shown by S. Amato, 09:58
Every request made in the room, and when what it asked for was shownRequest 14: what S. Amato showed, each the entity itself, not a copyThe room reaches Line 2, from Tue 22 Sep, and nothing outside itThe inspector reads and asks here, and cannot edit, sign or commentNothing in the room can be changedOnly what the inspection covers41,339 vials released. The lot's record, 8 of 8 steps signed, 1,912 entriesSterility takes 14 days. The endotoxin retest passed on Fri 13 NovFound by Neil, Mon 9 Nov 19:40: the record's step 4.3 against F-⁠02's readingsCovered by media fill MF-⁠26-⁠02. Step 4.4 of the lot's record14 settle and contact plates and the end-⁠of-⁠fill glove plates, read after five daysThe record's limit is 36 h; study EXP-⁠332, which covered 26 h, is being extended to 36 hLots 26-⁠0905, 0908, 0912 and 0914, corrected by dated late entries, never overwrittenChangeset #15, approved by S. Amato, QA. CAPA-⁠019 replaced the worn feed track on Sat 14 Nov

Questions about Seal Submissions.

Can we buy Seal Submissions today?

Not yet: it is a proposal. What it rests on is shipped: published documents at a version with their sign-offs and history, changesets, read-only access, sharing a published document with a named person, and Neil's drafts, which a person signs.

Does Neil submit anything?

No. Neil drafts and says what it could not find; a person approves, signs and sends.

Who signs a section or an answer?

The person who owns it, in Seal, with their password or passkey, as every signature in Seal is given. Neil signs nothing.

Is it an eCTD publishing tool?

No. Your publishing tool still builds and validates each sequence; Seal gives it each approved section, as a PDF at its version.

Can we keep our publishing tool and gateway?

Yes. Seal does not connect to an agency: your people send each sequence through your own gateway, as they do today.

What does an inspector see, and change?

Only what the inspection covers, read-only: they read and make requests, and cannot edit, sign or comment. Read-only access in Seal today blocks creating, editing, running, commenting and signing.

Can Neil be wrong?

Yes. Every statement opens at its source and version for the person who approves it to read, and where Neil cannot tie a line to a source it says so rather than filling it in.

We make for clients. Who files?

Your client. You draft each section or answer from your own record, approve it and send them a read-only copy, and they file it; nothing else of yours is open to them.

How does it relate to RIMS?

RIMS keeps registrations and each market's approved state, in Seal's RIMS blueprint or the one you have. Submissions is where a section's or an answer's content comes from: the record.

See your process in Seal.

Working 48 hours after we agree its scope: tested, with evidence your QA approves.